An update on biomarkers of potential benefit with bevacizumab for breast cancer treatment: Do we make progress?

ABSTRACT: As the first monoclonal antibody against vascular endothelial growth factor (VEGF), bevacizumab (BEV) is a definitely controversial antiangiogenic therapy in breast cancer. The initial excitement over improvements in progression-free survival (PFS) with BEV was tempered by an absence of overall survival (OS) benefit and serious adverse effects. Missing targeted population urged us to identify the predictive biomarkers for BEV efficacy. In this review we focus on the research in breast cancer and provide recent investigations on clinical, radiological, molecular and gene profiling markers of BEV efficacy, including the new results from randomized phase III clinical trials evaluating the efficacy of BEV in combination with comprehensive biomarker analyses. Current evidences indicate some pre

SUBMITTER: Liang X 

PROVIDER: S-EPMC6736652 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature